Clinical Research Directory

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed limited-stage small cell lung cancer (LS-SCLC) defined as Stage I-III by American Joint Committee on Cancer 9th Edition Cancer Staging * Has received appropriate definitive concurrent chemoradiotherapy (CRT; 4 cycles of platinum-based chemotherapy concurrent with radiotherapy) per protocol * Has achieved complete response, partial response, or stable disease and did not progress per protocol following definitive, platinum-based chemotherapy concurrent with radiotherapy * Is not expected to require tumor resection during the study * Is able to submit a biopsy of a tumor lesion not previously irradiated * Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART), if diagnosed with HIV * Has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy, if hepatitis B surface antigen-positive * Has undetectable hepatitis C virus (HCV) viral load, if has a history of HCV infection Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has received sequential CRT for LS-SCLC (no overlap of radiotherapy with chemotherapy) * Has clinical or radiographic progression or deterioration while on concurrent CRT * Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures * Has active or history of immune deficiency (with the exception of well-controlled HIV on ART) * Has history of Kaposi's sarcoma and/or Multicentric Castleman's Disease, if diagnosed with HIV * Is expected to require any other form of antineoplastic therapy while on study * Has known additional malignancy that is progressing or required active treatment within the past 3 years * Has known central nervous system metastases or leptomeningeal disease * Has active autoimmune disease that required systemic treatment in the past 2 years * Has active infection requiring systemic therapy (other than therapies permitted per protocol) * Has active or history of neurologic paraneoplastic syndrome * Has current pneumonitis/interstitial lung disease (ILD) or history of noninfectious pneumonitis/ILD that required steroids * Has uncontrolled or significant cardiovascular disease * Has clinically severe pulmonary compromise from intercurrent pulmonary illnesses * Has history of clinically significant intracranial or spinal cord bleeding * Has history of allogeneic tissue/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications